ImmuLogic Pharmaceutical Corp. (A): March 1991 Harvard Case Solution & Analysis

ImmuLogic Pharmaceutical Corporation, the development stage biotechnology company, is considering IPO of common stock. Different views entrepreneurs, venture capitalists, investment bankers and institutional investors are considered. Problems of assessment are highlighted. Problems associated with the "windows" for the public offering is considered. "Hide
by Josh Lerner Source: Harvard Business School 21 pages.

case solution" width="288" height="288" /> immulogic pharmaceutical corporation case solution

Publication Date: October 22, 1992. Prod. #: 293066-PDF-ENG

Related Case Solutions & Analyses:

Inner City Renovation: Rebuilding Properties, Lives and Communities Sport-Fresh Gels: Choosing a Path Housing.com: Disrupting the House Search Process in India Fiat Mio: The Project That Embraced Open Innovation, Crowdsourcing and Creative Commons in the Automotive Industry Integrative Programs in International Business: The Development of Undergraduate Cohort Programs Scoring Expert Forecasts Byrraju Foundation: SWEET Water Project Chile’s Copper Surplus: The Road Not Taken (A) Emerging Nokia? The U.S. Health Club Industry, 2005-2016